These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12201621)

  • 1. Choosing the right dopamine agonist for patients with Parkinson's disease.
    Lebrun-Frenay C; Borg M
    Curr Med Res Opin; 2002; 18(4):209-14. PubMed ID: 12201621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing dopamine agonists in Parkinson's disease.
    Tan EK; Jankovic J
    Clin Neuropharmacol; 2001; 24(5):247-53. PubMed ID: 11586109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
    Kuzel MD
    Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Choosing a dopamine agonist in Parkinson's disease].
    Bogucki A; Gajos A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S14-21. PubMed ID: 17941454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
    Luthra PM; Kumar JB
    Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists.
    Factor SA
    Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
    Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
    Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.